Premium
Mibefradil is a potent inhibitor of both CYP3A and P‐glycoprotein (P‐GP)
Author(s) -
Wandel C.,
Kim R.B.,
Guengerich F.P.,
Wood A.J.J.
Publication year - 1999
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/s0009-9236(99)80029-0
Subject(s) - p glycoprotein , mibefradil , pharmacology , clinical pharmacology , medicine , chemistry , biochemistry , receptor , antagonist , antibiotics , multiple drug resistance
Clinical Pharmacology & Therapeutics (1999) 65 , 124–124; doi: